It is questioned whether increasing the dose -- which is feasible due to the lower toxicity of eteplirsen compared to drisapersen -- would benefit the non-responders .
Whether this could result in any increased side effects .
It is questioned whether increasing the dose -- which is feasible due to the lower toxicity of eteplirsen compared to drisapersen -- would benefit the non-responders and whether this could result in any increased side effects .